Hanmi Pharm (KRX:128940) swung to a net loss attributable to shareholders of the parent company of 1.996 trillion won in the fourth quarter of 2024 from a net income of 34.4 billion won a year earlier.
The company's sales declined 16.7% year over year to 351.6 billion won from 422.4 billion won, according to a Korea Exchange filing.